Generic Firms Fear FDA Pill Size Guidance Helps Brands Stifle Competition
This article was originally published in The Tan Sheet
Executive Summary
FDA final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.
You may also be interested in...
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Generics must be able to be administered without provider intervention or patient retraining, draft guidance says.
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Generics must be able to be administered without provider intervention or patient retraining, draft guidance says.
FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns
FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.